New drug for myelofibrosis after JAK inhibitor failure
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have intermediate or high-risk myelofibrosis (primary or secondary).
- You have tried a JAK inhibitor (like ruxolitinib) and it didn't work well enough, or you cannot take one.
- Your spleen is enlarged (measurable on exam or imaging).
- You have active symptoms from myelofibrosis (like severe night sweats, itching, or pain).
- Your blood counts, kidney, and liver function are within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.